Content area
Full Text
Cancer Causes and Control (2005) 16:255262 Springer 2005
DOI 10.1007/s10552-004-3484-8Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of
prostate cancer in the PSA eraqElizabeth A. Platz1,*, Michael N. Pollak2, Michael F. Leitzmann3, Meir J. Stampfer4, Walter C. Willett4 & Edward
Giovannucci41Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; and the Brady Urological Institute
and the Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD;2CancerPrevention Research Unit, Departments of Medicine and Oncology, Jewish General Hospital and McGill University,
Montreal, Canada;3Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of
Health, Department of Health and Human Services, Bethesda, MD USA;4Departments of Nutrition andEpidemiology, Harvard School of Public Health, and the Channing Laboratory, Department of Medicine, Harvard
Medical School and Brigham & Womens Hospital, Boston, MAReceived 13 May 2004; accepted in revised form 20 September 2004Key words: cohort study, insulin-like growth factor, prostate cancer, risk.AbstractObjective: The insulin-like growth factor (IGF) axis is thought to contribute to the growth and progression of
prostate cancer. Some prospective studies support a direct association between IGF-1 and prostate cancer, in
particular advanced disease, whereas both inverse and direct associations with prostate cancer have been reported
for insulin-like growth factor binding protein-3 (IGFBP-3), the major IGF-1 binding protein in circulation. We
prospectively investigated the associations of plasma IGF-1 and IGFBP-3 concentrations with prostate cancer
detected in the PSA era.Methods: We identied 462 prostate cancer cases diagnosed after providing a blood specimen in 1993, but before
January 1998 among men in the Health Professionals Follow-up Study. Controls were 462 age-matched men
without prostate cancer who had had a PSA test after providing a blood specimen. We measured plasma
concentrations of IGF-1 and IGFBP-3 by ELISA. Conditional logistic regression was used to estimate odds ratios
(OR) and 95% condence intervals (CI) of prostate cancer.Results: Men with higher concentrations of IGF-1 (comparing extreme quartiles OR 1.37, 95% CI 0.922.03, p-trend 0.05) and IGFBP-3 (OR 1.62, 95% CI 1.072.46, p-trend 0.08) had a higher risk of prostate cancer.
After mutual statistical adjustment, these associations were attenuated for both IGF-1 (OR 1.17, 95% CI 0.691.99, p-trend 0.29) and IGFBP-3 (OR 1.40, 95% CI 0.802.44, p-trend 0.56). We found no signicant
association of IGF-1 with regionally invasive or metastatic (T3b, N1, or...